ARA-290

ARA-290 is a non-erythropoietic peptide derived from erythropoietin that targets the innate repair receptor (IRR) to reduce inflammation and promote healing, particularly in neuropathic pain, cardiovascular inflammation, and microvascular dysfunction. It avoids stimulating red blood cell production, making it safer for chronic therapeutic use.

• Reduces inflammation
• Promotes tissue repair
• Binds to the innate repair receptor (IRR) composed of EPO-R and CD131
• Suppresses microglial activation in the spinal cord
• Reduces pro-inflammatory cytokine activity
• Improves microvascular function and nerve regeneration

• unit: mg

  low dose: 1

  frequency: daily

  high dose: 8

  standard dose: 4

  administration route: Subcutaneous (SQ)

• Recommended frequency: 3–5x per week with a suggested cycle length of 4–8 weeks, followed by reevaluation.

common: ["Transient headache, mild dizziness (human trial)","Fatigue after dosing (human trial)","Mild GI discomfort (human trial)"]

sequence: Ac-VSPKVGSEAEABQPLPLRSLS

half life: Approximately 2 hours

degradation: Mainly metabolized by endothelial cells and degraded by proteases.

molecular weight: 14179.3

molecular formula: C141H210N38O41

tissue specificity: Interacts primarily with nervous and immune tissues to exert protective and reparative effects.

• ARA 290 improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.clinicalPMID 25387363 ↗
• ARA 290 relieves pathophysiological pain by targeting TRPV1 channel.mechanismPMID 26774587 ↗
• ARA 290 for treatment of small fiber neuropathy in sarcoidosis.reviewPMID 24555851 ↗